Microtransplantation Outcomes for Older AML Patients, Single-Center Study 2008-2021

A single-center clinical study of 29 patients aged 60 and over with newly diagnosed acute myeloid leukemia (AML) treated with microtransplantation between April 2008 and June 2021. The dataset includes endpoints such as complete remission rates, overall survival, leukemia-free survival, relapse, and non-relapse mortality, with a median follow-up of 148.5 months. The data was published by Juan Liu under a CC-BY-4.0 license.

Use Cases

• Modeling overall survival (OS) and leukemia-free survival (LFS) based on patient age cohorts (60-70 vs. >70 years).
• Analyzing the association between the number of treatment courses (>3) and improved patient outcomes.
• Investigating the cumulative incidence of relapse and non-relapse mortality using competing risk analysis methods.
• Exploring transcriptomic profiles for immune and hematopoietic pathways in a subset of long-term survivors.

Strengths

• Long-term follow-up with a median of 148.5 months (over 12 years).
• Includes detailed clinical endpoints: complete remission rate of 86.2%, median OS of 20.00 months.
• Patient stratification into two age cohorts (n=20 and n=9) allows for comparative analysis.

Limitations

• Row count is unknown, which may limit suitability assessment.
• Column-level documentation is absent; field semantics must be inferred after download.
• Data is from a single-center study with 29 patients, limiting generalizability.

Provenance

Source

figshare, author Juan Liu.

Collection Method

Clinical data collected from a single-center study.

Time Range

April 2008 to June 2021, with follow-up data.

Freshness

Last updated 2026-03-18 07:39:50; freshness should be verified.

Geography

Single-center location not specified; likely reflects a specific hospital's patient population.